Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab

Circ Heart Fail. 2016 Oct;9(10):e003514. doi: 10.1161/CIRCHEARTFAILURE.116.003514.
No abstract available

Keywords: adverse events; heart failure; immune checkpoint inhibitor; melanoma; myocarditis.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Biopsy
  • Choroid Neoplasms / drug therapy*
  • Choroid Neoplasms / immunology
  • Choroid Neoplasms / pathology
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunohistochemistry
  • Lymphocytosis / chemically induced*
  • Lymphocytosis / diagnosis
  • Lymphocytosis / drug therapy
  • Lymphocytosis / physiopathology
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / secondary
  • Myocarditis / chemically induced*
  • Myocarditis / diagnosis
  • Myocarditis / drug therapy
  • Myocarditis / physiopathology
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • Glucocorticoids
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab